BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma has achieved significant milestones, including FDA approval for NULIBRY™ (fosdenopterin) as the first treatment for molybdenum cofactor deficiency Type A. The company reported proof-of-concept data for encaleret in Autosomal Dominant Hypocalcemia Type 1. A collaboration with Helsinn Group aims to co-develop infigratinib in oncology, with potential earnings of up to $2.45 billion. The completion of Eidos Therapeutics acquisition and the issuance of $750 million in Convertible Senior Notes bolster financial stability, ending Q1 2021 with $1 billion in cash and securities.
BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC San Diego to translate research in genetically driven conditions into therapeutic applications, focused on oncology and neurology. The collaboration aims to identify promising research programs and potentially sponsor them for clinical investigation. This partnership is part of BridgeBio's commitment to develop life-changing medicines for patients, utilizing its developmental expertise alongside UC San Diego's research capabilities. BridgeBio currently has 20 partnerships with leading academic institutions.
BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC Davis to enhance research and development for genetic diseases and cancers. The collaboration aims to explore and assess potential research projects in genetic disorders and precision oncology. BridgeBio emphasizes its commitment to translating innovative research into effective treatments, leveraging its partnerships with various academic institutions. This alliance marks a strategic move to expand BridgeBio’s initiatives in developing therapies for genetically driven conditions, enhancing its portfolio of over 30 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with Roswell Park Comprehensive Cancer Center to develop investigational therapies for genetically driven cancers. This partnership marks a significant step in BridgeBio's efforts to advance cancer treatment, allowing for new research opportunities and accelerated clinical pathways. The collaboration is part of BridgeBio's broader strategy to engage with leading academic institutions to translate scientific discoveries into effective treatments efficiently.
BridgeBio Pharma (NASDAQ: BBIO) announced a collaboration with Oregon Health & Science University (OHSU) to develop investigational therapies for genetically driven conditions. This partnership extends five years of informal collaboration and aims to leverage OHSU's research capabilities to advance potential treatments for diseases like cancer. The collaboration underscores BridgeBio's commitment to rapidly translating genetic research into clinical applications, enhancing its portfolio of over 30 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with The Lundquist Institute to develop treatments for genetically driven diseases and cancers. This two-year partnership aims to harness Lundquist's research capabilities and BridgeBio's resources to identify potential therapies. The partnership extends BridgeBio's network to 20 academic and research institutions, emphasizing their commitment to pioneering medicines for patients. CEO Neil Kumar expressed optimism about translating scientific discoveries into meaningful treatments.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with the Canadian Glycomics Network (GlycoNet) aimed at translating glycomics research into treatments for genetic diseases. The partnership intends to foster research programs and clinical investigations, leveraging glycomics insights for therapeutic advancements. BridgeBio has previously partnered with various academic institutions, enhancing its research capabilities. This collaboration is expected to streamline the development of treatments for genetic disorders, addressing unmet medical needs.
BridgeBio Pharma (NASDAQ: BBIO) has partnered with Brown University to enhance research in genetically driven neurological disorders. The collaboration aims to advance treatment methods for complex brain diseases, leveraging Brown's neurology expertise. Under this partnership, promising discoveries will be evaluated, with opportunities for Brown scientists to take leadership roles in developing therapeutic programs. This collaboration is part of BridgeBio's strategy to translate genetic research into viable medicines, complementing its existing 20 partnerships with leading academic institutions.
BridgeBio Pharma granted restricted stock units totaling 32,691 shares to 19 new employees, as part of its 2019 Inducement Equity Plan. The awards were announced on April 5, 2021, following Nasdaq Listing Rule 5635(c)(4), which requires such grants as inducements for employees entering the company. BridgeBio focuses on developing transformative medications for genetic diseases and cancers, with a pipeline of over 30 development programs from early science to advanced clinical trials.
BridgeBio and Helsinn have entered a global collaboration to co-commercialize infigratinib for oncology, sharing profits equally. Helsinn will exclusively develop and commercialize infigratinib outside the U.S., excluding China and nearby regions. BridgeBio stands to gain over $2 billion in milestone payments. The FDA has granted Priority Review for infigratinib for cholangiocarcinoma, highlighting its potential in treating FGFR-driven cancers. This partnership aims to accelerate the launch and broaden research into infigratinib's applications.